These findings position FABP5 as a central mediator of metabolic-immune crosstalk in HCC, offering a promising therapeutic target to counteract tumor-associated immunosuppression by modulating lipid metabolism in macrophages. This evidence concerns the gene FABP5 and hepatocellular carcinoma.